Metoclopramidum Polpharma (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, decreasing the stimulus for nausea. In the gastrointestinal tract it enhances acetylcholine release, stimulating smooth‑muscle contraction and accelerating gastric emptying, which helps alleviate reflux and gastroparesis.

The appropriate dose of Metoclopramidum Polpharma is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Dosage regimens can vary, and the prescriber will provide specific instructions.

Data on metoclopramide use in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other antiemetics such as ondansetron, metoclopramide adds a gastroprokinetic effect by promoting gastric motility, which can be advantageous in gastroparesis. However, it carries a higher risk of extrapyramidal side effects, so clinicians balance efficacy against safety when selecting therapy.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain stability throughout the shelf life.

Metoclopramidum Polpharma is taken orally, usually with a glass of water. It may be administered with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals.

Serious adverse reactions include extrapyramidal symptoms such as dystonia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome, a rare but life‑threatening condition. Immediate medical attention is required if any of these signs appear.

Patients with known hypersensitivity to metoclopramide, those taking antipsychotics that cause dopamine blockade, individuals with pheochromocytoma, and patients with severe gastrointestinal obstruction should avoid this medication. Contra‑indications are confirmed by the prescribing clinician.